Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg of Dr. Reddy's Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier:
NCT01506076
First received: January 5, 2012
Last updated: January 6, 2012
Last verified: January 2012
  Purpose

The purpose of this study is to assess the Bioequivalence of Levocetirizine DiHCl Tablets 5mg with XYZAL tablets 5 mg and to monitor clinical status, adverse events and laboratory investigations and assess relative safety and tolerance, under fasting conditions.


Condition Intervention Phase
Fasting
Drug: Levocetirizine DiHCl
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Levocetirizine DiHCl Tablets 5mg With XYZAL® Tablets 5 mg in Healthy Subjects Under Fasting Conditions

Resource links provided by NLM:


Further study details as provided by Dr. Reddy's Laboratories Limited:

Primary Outcome Measures:
  • Bioequivalence is based on Cmax and AUC parameters [ Time Frame: 2 month ] [ Designated as safety issue: No ]

Enrollment: 29
Study Start Date: December 2007
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Levocetirizine DiHCl Tablets, 5 mg
Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
Drug: Levocetirizine DiHCl
Levocetirizine DiHCl Tablets 5 mg
Other Name: XYZAL
Active Comparator: XYZAL
XYZAL Tablets 5 mg of UCB Farchim S.A.
Drug: Levocetirizine DiHCl
Levocetirizine DiHCl Tablets 5 mg
Other Name: XYZAL

Detailed Description:

A pivotal study to compare the Bioequivalence of Levocetirizine DiHCl Tablets 5 mg of Dr.Reddy's Laboratories Limited with XYZAL® Tablets 5 mg of UCB Farchim S.A. in healthy, human subjects under fasting conditions.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects will provide written informed consent.
  • Subjects must be healthy adults within 18-45 years of age (inclusive).
  • Body mass index of ≥18.5 kg/m2 and ≤25 kg/m2, with body weight not less than 50 kg.
  • Subjects must be of normal health as determined by medical history and physical examination performed within 15 days prior to the commencement of the dosing in Period-I.
  • Have normal ECG, chest X-Ray and vital signs and clinically non significant changes in ECG & chest X-Ray.
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
  • Subjects will be Non smokers or moderate smokers (less than 10 cigarettes a day) for at least 6 months.
  • If subject is a female volunteer and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device(IUD), or abstinence.

or is postmenopausal for at least 1 year. is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject)

•Each female subject will be given a urine pregnancy test at screening, check-in for period-1, period-2 and post study.

Exclusion Criteria:

  • Subjects incapable of understanding the informed consent.
  • Subjects with BP lesser than 90/60 mm of Hg or BP greater than or equal to 140/90 mm of Hg.
  • History of hypersensitivity or idiosyncratic reaction to Levocetirizine or other related drugs.
  • Any evidence of impairment of renal, hepatic, gastro intestinal, lung and cardiac function.
  • Subjects with a history of tuberculosis, epilepsy, asthma (during past 5 years), diabetes, psychosis or glaucoma will not be eligible for the study.
  • Regular smoker who smokes more than ten cigarettes daily or has difficulty in abstaining from smoking for the duration of each study period.
  • Subjects who have taken over the counter or prescribed medications, including any enzyme modifying drugs or any systemic medication within the past two weeks prior to prior to dosing in Period-1.
  • History of any psychiatric illness, which may impair the ability to provide written, informed consent.
  • Subject is mentally or legally incapacitated, or has a history of significant psychiatric disorder.
  • Subjects who have a history of alcohol or substance/ drug of abuse within the last 5 years.
  • Subjects with clinically significant abnormal values of laboratory parameters, including positive results of HIV, HBV, HCV, RPR tests.
  • Subjects who participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months.
  • Subjects who are unable to or likely to be non-compliant with protocol requirements or restrictions.
  • Subjects who are intolerant to venipuncture.
  • Any subject in whom Levocetirizine Dihydrochloride is contraindicated for medical reasons.
  • Female volunteers who has used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.
  • Female volunteers demonstrating a positive pregnancy screen.
  • All female subjects will be screened for pregnancy at screening, check-in each study period. Subjects with positive or inconclusive results will be withdrawn from the study.
  • Female volunteers who are currently breast feeding. Female subjects who are pregnant, breast-feeding or who are likely to become pregnant during the study will not be allowed to participate. Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of contraception during the course of the study (first dosing until last blood collection) or they will not be allowed to participate.
  • Subjects with positive urine screen for drugs of abuse at the time of admission check-in for each period will be excluded from the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01506076

Locations
India
Vimta Labs Ltd.,
Hyderabad, A.P, India, 500 051
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Investigators
Principal Investigator: Sudershan Vishwanath, MD Vimta Labs Ltd.,
  More Information

No publications provided

Responsible Party: Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier: NCT01506076     History of Changes
Other Study ID Numbers: 07446/07-08
Study First Received: January 5, 2012
Last Updated: January 6, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Levocetirizine
Cetirizine
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Anti-Allergic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on September 16, 2014